The role of innate immunity in MDS pathogenesis

por Sallman, David A., List, Alan
Publicado 2019

PP2A: The Achilles Heal in MDS with 5q Deletion

por Sallman, David A., Wei, Sheng, List, Alan
Publicado 2014

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes

por Clara, Joseph A., Sallman, David A., Padron, Eric
Publicado 2016

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

por Sallman, David A., Cluzeau, Thomas, Basiorka, Ashley A., List, Alan
Publicado 2016

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

por Cluzeau, Thomas, Loschi, Michael, Fenaux, Pierre, Komrokji, Rami, Sallman, David A.
Publicado 2021

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

por Brunner, Andrew M., Gavralidis, Alexander, Ali, Najla Al, Hunter, Anthony, Komrokji, Rami, Zeidan, Amer, Sallman, David A.
Publicado 2022

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

por Komrokji, Rami, al Ali, Najla, Chan, Onyee, Sweet, Kendra, Kuykendall, Andrew, Lancet, Jeffrey, Padron, Eric, Sallman, David A.
Publicado 2022

Integrative molecular subtypes of acute myeloid leukemia

por Mo, Qianxing, Yun, Seongseok, Sallman, David A., Vincelette, Nicole D., Peng, Guang, Zhang, Ling, Lancet, Jeffrey E., Padron, Eric
Publicado 2023

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

por Komrokji, Rami S., Singh, Avani M., Ali, Najla Al, Chan, Onyee, Padron, Eric, Sweet, Kendra, Kuykendall, Andrew, Lancet, Jeffrey E., Sallman, David A.
Publicado 2022

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS

por Sallman, David A, Komrokji, Rami, Cluzeau, Thomas, Vaupel, Christine, Al Ali, Najla H, Lancet, Jeffrey, Hall, Jeff, List, Alan, Padron, Eric, Song, Jinming
Publicado 2017

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

por Komrokji, Rami S., Aguirre, Luis E., Al Ali, Najla H., Chan, Onyee, Xie, Zhuoer, Kuykendall, Andrew, Sweet, Kendra, Lancet, Jeffrey E., Padron, Eric, Sallman, David A.
Publicado 2023

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

por Daver, Naval G., Maiti, Abhishek, Kadia, Tapan M., Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H., Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A., Kantarjian, Hagop M.
Publicado 2022

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

por Jain, Akriti G, Dong, Ning C., Ball, Somedeb, Tan, Elaine S, Whiting, Junmin, Komrokji, Rami S., Sweet, Kendra, Chan, Onyee, Sallman, David A., Padron, Eric, Kuykendall, Andrew T., Giuliano, Anna, Lancet, Jeffrey E.
Publicado 2021

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning

por Sallman, David A., Bejar, Rafael, Montalban-Bravo, Guillermo, Kurtin, Sandra E., List, Alan F., Garcia-Manero, Guillermo, Nimer, Stephen D., O'Connell, Casey L., Schaar, Dale, Butchko, Janice, Iraca, Tracey, Searle, Stephanie
Publicado 2022

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

por McGraw, Kathy L., Cluzeau, Thomas, Sallman, David A., Basiorka, Ashley A., Irvine, Brittany A., Zhang, Ling, Epling-Burnette, P.K., Rollison, Dana E., Mallo, Mar, Sokol, Lubomir, Solé, Francesc, Maciejewski, Jaroslaw, List, Alan F.
Publicado 2015

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

por Wang, Chen, McGraw, Kathy L., McLemore, Amy F., Komrokji, Rami, Basiorka, Ashley A., Al Ali, Najla, Lancet, Jeffrey E., Padron, Eric, Kosmider, Olivier, Fontenay, Michaela, Fenaux, Pierre, List, Alan F., Sallman, David A.
Publicado 2021

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes

por Cheng, Pinyang, Eksioglu, Erika A., Chen, Xianghong, Kandell, Wendy, Le Trinh, Thu, Cen, Ling, Qi, Jin, Sallman, David A., Zhang, Yu, Tu, Nhan, Adams, William A., Zhang, Chunze, Liu, Jinhong, Cleveland, John L., List, Alan F., Wei, Sheng
Publicado 2019

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metast...

por Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F
Publicado 2017

Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes

por McLemore, Amy F., Hou, Hsin-An, Meyer, Benjamin S., Lam, Nghi B., Ward, Grace A., Aldrich, Amy L., Rodrigues, Matthew A., Vedder, Alexis, Zhang, Ling, Padron, Eric, Vincelette, Nicole D., Sallman, David A., Abdel-Wahab, Omar, List, Alan F., McGraw, Kathy L.
Publicado 2022

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

por Radakovich, Nathan, Sallman, David A., Buckstein, Rena, Brunner, Andrew, Dezern, Amy, Mukerjee, Sudipto, Komrokji, Rami, Al-Ali, Najla, Shreve, Jacob, Rouphail, Yazan, Parmentier, Anne, Mamedov, Alexandre, Siddiqui, Mohammed, Guan, Yihong, Kuzmanovic, Teodora, Hasipek, Metis, Jha, Babal, Maciejewski, Jaroslaw P., Sekeres, Mikkael A., Nazha, Aziz
Publicado 2022